Table 1.
Overall features of included participants (N = 37)*.
| Characteristics | |
|---|---|
| Socio-demographic | |
| Median [IQR] age (years), | 49 [39–57] |
| Male, n (%) | 22 (58) |
| Immuno-virological parameters | |
| Median CD4 count (cell/mm3), | 173 [34–374] |
| Median VL (copies/ml), | 169,322 [30, 382–551, 826] |
| HIV-1 genetic diversity (%) | |
| Pure subtypes | 28.97 |
| Circulating recombinant form | 71.03 |
| Third-line ART regimens (%) | |
| TDF + 3TC + DTG + DRV/r51.3 | |
| TDF + 3TC + DRV/r13.5 | |
| TDF + 3TC + DTG | 8.1 |
| TDF + 3TC + DTG + ATV/r | 5.4 |
| TDF + 3TC + DTG + LPV/r | 5.4 |
| AZT + 3TC + DTG + ATV/r | 8.1 |
| ABC + 3TC + DTG + DRV/ r | 2.7 |
| ABC + 3TC + DRV/r + ATV/r | 2.7 |
| DTG + DRV/r + ETR | 2.7 |
| Median time on third-line therapy (mo) | 21 [17–32] |
% = percentage, 3TC = lamivudine, ABC = abacavir; ART = antiretroviral therapy, ATV/r = ritonavir-boosted atazanavir, AZT = zidovudine, CD = clusters of differentiation, CD4 = cluster of differentiation type 4, DRV/r = ritonavir-boosted darunavir, DTG = dolutegravir, ETR = etravirine, HIV = human immunodeficiency virus, IQR = interquartile range, LPV/r = ritonavir-boosted lopinavir, n = number, TDF = tenofovir, VL = viral load.
one participant did not have a clear treatment history regarding third-line prescription and was not included in this table. However, as previous treatment history as well as genotypic resistance results at 3L initiation were available we did not exclude him from the global analysis (therefore N = 37 here in this table but N = 38 in the study).